Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease

Brain Research Reviews

Volumn 50, Issue 1, 2005, Pages 156-168

  Deogaonkar, Milind ^a   Subramanian, Thyagarajan ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Basal ganglia; Dyskinesia; Levodopa; MPTP; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; BROMOCRIPTINE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR; ETIRACETAM; LEVODOPA; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPEPTIDE; PRAMIPEXOLE; RISPERIDONE; RITANSERIN; ROPINIROLE; SELEGILINE; TERGURIDE; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2;

BASAL GANGLION; DRUG INDUCED DISEASE; DYSKINESIA; ELECTROPHYSIOLOGY; HUMAN; PALLIDOTOMY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION; THALAMOTOMY;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; HUMANS; MODELS, BIOLOGICAL; NEUROPEPTIDES; PARKINSON DISEASE; RECEPTORS, NEUROTRANSMITTER;

EID: 27744564201     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2005.05.005     Document Type: Review

References (149)

1. G.M. Alexander, R.J. Schwartzman, J.R. Grothusen, L. Brainard, and S.W. Gordon Changes in brain dopamine receptors in MPTP parkinsonian monkeys following l-dopa treatment Brain Res. 625 1993 276 282
2. M. Andersson, A. Hilbertson, and M.A. Cenci Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease Neurobiol. Dis. 6 1999 461 474
3. R.A. Bakay, C.D. Raiser, N.P. Stover, T. Subramanian, M.L. Cornfeldt, A.W. Schweikert, R.C. Allen, and R. Watts Implantation of spheramine in advanced Parkinson's disease (PD) Front. Biosci. 9 2004 592 602
4. M.S. Baron, J.L. Vitek, R.A. Bakay, J. Green, Y. Kaneoke, T. Hashimoto, R.S. Turner, J.L. Woodard, S.A. Cole, W.M. McDonald, and M.R. DeLong Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study Ann. Neurol. 40 1996 355 366
5. M.S. Baron, J.L. Vitek, R.A. Bakay, J. Green, W.M. McDonald, S.A. Cole, and M.R. DeLong Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study Mov. Disord. 15 2000 230 237
6. F. Baronti, M.M. Mouradian, K.E. Conant, M. Giuffra, G. Brughitta, and T.N. Chase Partial dopamine agonist therapy of levodopa-induced dyskinesias Neurology 42 1992 1241 1243
7. P.J. Bedard, T. Di Paolo, P. Falardeau, and R. Boucher Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding Brain Res. 379 1986 294 299
8. A.L. Benabid, P. Pollak, C. Gross, D. Hoffmann, A. Benazzouz, D.M. Gao, A. Laurent, M. Gentil, and J. Perret Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease Stereotact. Funct. Neurosurg. 62 1994 76 84
9. A.L. Benabid, A. Benazzouz, P. Limousin, A. Koudsie, P. Krack, B. Piallat, and P. Pollak Dyskinesias and the subthalamic nucleus Ann. Neurol. 47 2000 S189 S192
10. A.L. Benabid, A. Koudsie, A. Benazzouz, L. Vercueil, V. Fraix, S. Chabardes, J.F. Lebas, and P. Pollak Deep brain stimulation of the corpus luysi (subthalamic nucleus) and other targets in Parkinson's disease. Extension to new indications such as dystonia and epilepsy J. Neurol. 248 Suppl. 3 2001 III37 III47
11. H. Bergman, T. Wichmann, and M.R. DeLong Reversal of experimental parkinsonism by lesions of the subthalamic nucleus Science 249 1990 1436 1438
12. E. Bezard, T. Boraud, S. Chalon, J.M. Brotchie, D. Guilloteau, and C.E. Gross Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey Neuroscience 103 2001 117 123
13. P.J. Blanchet, S.M. Papa, L.V. Metman, M.M. Mouradian, and T.N. Chase Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease Neurosci. Biobehav. Rev. 21 1997 447 453
14. P.J. Blanchet, S. Konitsiotis, and T.N. Chase Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys Mov. Disord. 13 1998 798 802
15. P.J. Blanchet, S. Konitsiotis, E.R. Whittemore, Z.L. Zhou, R.M. Woodward, and T.N. Chase Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys J. Pharmacol. Exp. Ther. 290 1999 1034 1040
16. P.J. Blanchet, L.V. Metman, and T.N. Chase Renaissance of amantadine in the treatment of Parkinson's disease Adv. Neurol. 91 2003 251 257
17. P.J. Blanchet, F. Calon, M. Morissette, A.H. Tahar, N. Belanger, P. Samadi, R. Grondin, L. Gregoire, L. Meltzer, T.D. Paolo, and P.J. Bedard Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms Parkinsonism Relat. Disord. 10 2004 297 304
18. G. Block, C. Liss, S. Reines, J. Irr, and D. Nibbelink Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group Eur. Neurol. 37 1997 23 27
19. T. Boraud, E. Bezard, D. Guehl, B. Bioulac, and C. Gross Effects of l-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey Brain Res. 787 1998 157 160
20. R. Bordet, S. Ridray, S. Carboni, J. Diaz, P. Sokoloff, and J.C. Schwartz Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa Proc. Natl. Acad. Sci. U. S. A. 94 1997 3363 3367
21. N. Breysse, C. Baunez, W. Spooren, F. Gasparini, and M. Amalric Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism J. Neurosci. 22 2002 5669 5678
22. J.M. Brotchie, and S.H. Fox Quantitative assessment of dyskinesias in subhuman primates Mov. Disord. 14 Suppl. 1 1999 40 47
23. F. Calon, and T. Di Paolo Levodopa response motor complications-GABA receptors and preproenkephalin expression in human brain Parkinsonism Relat. Disord. 8 2002 449 454
24. F. Calon, M. Morissette, M. Goulet, R. Grondin, P.J. Blanchet, P.J. Bedard, and T. Di Paolo Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content Neurochem. Int. 35 1999 81 91
25. F. Calon, R. Grondin, M. Morissette, M. Goulet, P.J. Blanchet, T. Di Paolo, and P.J. Bedard Molecular basis of levodopa-induced dyskinesias Ann. Neurol. 47 2000 S70 S78
26. F. Calon, S. Birdi, A.H. Rajput, O. Hornykiewicz, P.J. Bedard, and P.T. Di Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias J. Neuropathol. Exp. Neurol. 61 2002 186 196
27. F. Calon, A.H. Rajput, O. Hornykiewicz, P.J. Bedard, and T. Di Paolo Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease Neurobiol. Dis. 14 2003 404 416
28. F. Calon, M. Dridi, O. Hornykiewicz, P.J. Bedard, A.H. Rajput, and T. Di Paolo Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias Brain 127 2004 1075 1084
29. M.A. Cenci Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease Amino Acids 23 2002 105 109
30. M.A. Cenci, C.S. Lee, and A. Bjorklund l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
31. M.A. Cenci, I.Q. Whishaw, and T. Schallert Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3 2002 574 579
32. T.N. Chase, E.M. Holden, and J.A. Brody Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis Arch. Neurol. 29 1973 328 333
33. T.N. Chase, F. Baronti, G. Fabbrini, I.J. Heuser, J.L. Juncos, and M.M. Mouradian Rationale for continuous dopaminomimetic therapy of Parkinson's disease Neurology 39 1989 7 10 (discussion 19)
34. T.N. Chase, T.M. Engber, and M.M. Mouradian Striatal dopaminoceptive system changes and motor response complications in l-dopa-treated patients with advanced Parkinson's disease Adv. Neurol. 60 1993 181 185
35. T.N. Chase, M.M. Mouradian, and T.M. Engber Motor response complications and the function of striatal efferent systems Neurology 43 1993 S23 S27
36. T.N. Chase, F. Bibbiani, W. Bara-Jimenez, T. Dimitrova, and J.D. Oh-Lee Translating A2A antagonist KW6002 from animal models to parkinsonian patients Neurology 61 2003 S107 S111
37. E. Check Parkinson's transplant therapy faces setback Nature 424 2003 987
38. J.F. Chen The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment Drug News & Perspect. 16 2003 597 604
39. J.F. Chen, S. Fredduzzi, E. Bastia, L. Yu, R. Moratalla, E. Ongini, and M.A. Schwarzschild Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease Neurology 61 2003 S74 S81
40. G.C. Cotzias, P.S. Papavasiliou, and R. Gellene Modification of Parkinsonism-Chronic treatment with l-dopa N. Engl. J. Med. 280 1969 337 345
41. S. Cristina, R. Zangaglia, F. Mancini, E. Martignoni, G. Nappi, and C. Pacchetti High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias Clin. Neuropharmacol. 26 2003 146 150
42. M.L. De Ceballos, and J.J. Lopez-Lozano Subgroups of parkinsonian patients differentiated by peptidergic immunostaining of caudate nucleus biopsies Peptides 20 1999 249 257
43. M. Deogaonkar, B. Piallat, and T. Subramanian Effect of l-dopa on neuronal activity of subthalamic nucleus and substantia nigra in hemiparkinsonian monkeys Mov. Disord. 20 2005 S75
44. O. Detante, L. Vercueil, P. Krack, S. Chabardes, A.L. Benabid, and P. Pollak Off-period dystonia in Parkinson's disease but not generalized dystonia is improved by high-frequency stimulation of the subthalamic nucleus Adv. Neurol. 94 2004 309 314
45. D.A. Di Monte, A. McCormack, G. Petzinger, A.M. Janson, M. Quik, and W.J. Langston Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model Mov. Disord. 15 2000 459 466
46. R. Duvoisin Hyperkinetic reactions with l-DOPA M. Yahr Current Concepts in Treatment of Parkinsonism 1974 Raven Press New York 203 210
47. A. Fernandez, M.L. de Ceballos, S. Rose, P. Jenner, and C.D. Marsden Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease Brain 119 Pt. 3 1996 823 830
48. M. Filion, L. Tremblay, and P.J. Bedard Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism Brain Res. 547 1991 152 161
49. S. Fox, M. Silverdale, M. Kellett, R. Davies, M. Steiger, N. Fletcher, A. Crossman, and J. Brotchie Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease Mov. Disord. 19 2004 554 560
50. J.A. Fritschi, T. Lauterburg, and J.M. Burgunder Expression of neurotransmitter genes in motor regions of the dyskinetic rat after iminodipropionitrile Neurosci. Lett. 347 2003 45 48
51. R.E. Gross, A.M. Lozano, A.E. Lang, R.R. Tasker, W.D. Hutchison, and J.O. Dostrovsky The effects of pallidotomy on Parkinson's disease: study design and assessment techniques Acta Neurochir., Suppl. (Wien) 68 1997 24 28
52. A. Hadj Tahar, L. Gregoire, A. Darre, N. Belanger, L. Meltzer, and P.J. Bedard Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys Neurobiol. Dis. 15 2004 171 176
53. I. Hamada, and M.R. DeLong Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs J. Neurophysiol. 68 1992 1850 1858
54. B. Henry, and J.M. Brotchie Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease Drugs Aging 9 1996 149 158
55. M.P. Hill, E. Bezard, S.G. McGuire, A.R. Crossman, J.M. Brotchie, A. Michel, R. Grimee, and H. Klitgaard Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by l-dopa and ropinirole in the MPTP-lesioned marmoset Mov. Disord. 18 2003 1301 1305
56. M.P. Hill, P. Ravenscroft, E. Bezard, A.R. Crossman, J.M. Brotchie, A. Michel, R. Grimee, and H. Klitgaard Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease J. Pharmacol. Exp. Ther. 310 2004 386 394
57. J.L. Houeto, M.L. Welter, P.B. Bejjani, S. Tezenas du Montcel, A.M. Bonnet, V. Mesnage, S. Navarro, B. Pidoux, D. Dormont, P. Cornu, and Y. Agid Subthalamic stimulation in Parkinson disease: intraoperative predictive factors Arch. Neurol. 60 2003 690 694
58. R. Inzelberg, E. Schechtman, and P. Nisipeanu Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison Drugs Aging 20 2003 847 855
59. B. Jarraya, A.M. Bonnet, C. Duyckaerts, J.L. Houeto, P. Cornu, J.J. Hauw, and Y. Agid Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study Mov. Disord. 18 2003 1517 1520
60. P. Jenner A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD Neurology 61 2003 S32 S38
61. P. Jenner The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications Neurology 61 2003 S4 S11
62. H. Kase, S. Aoyama, M. Ichimura, K. Ikeda, A. Ishii, T. Kanda, K. Koga, N. Koike, M. Kurokawa, Y. Kuwana, A. Mori, J. Nakamura, H. Nonaka, M. Ochi, M. Saki, J. Shimada, T. Shindou, S. Shiozaki, F. Suzuki, M. Takeda, K. Yanagawa, P.J. Richardson, P. Jenner, P. Bedard, E. Borrelli, R.A. Hauser, and T.N. Chase Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease Neurology 61 2003 S97 S100
63. Y. Katayama Deep brain stimulation (DBS) therapy for parkinson's disease Nippon Rinsho 58 2000 2078 2083
64. Y. Katayama, M. Kasai, H. Oshima, C. Fukaya, T. Yamamoto, and T. Mizutani Double blinded evaluation of the effects of pallidal and subthalamic nucleus stimulation on daytime activity in advanced Parkinson's disease Parkinsonism Relat. Disord. 7 2000 35 40
65. Y. Katayama, M. Kasai, H. Oshima, C. Fukaya, T. Yamamoto, K. Ogawa, and T. Mizutani Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients J. Neurosurg. 95 2001 213 221
66. R. Klintenberg, P. Svenningsson, L. Gunne, and P.E. Andren Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism J. Neural. Transm. 109 2002 1295 1307
67. S. Konitsiotis, P.J. Blanchet, L. Verhagen, E. Lamers, and T.N. Chase AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys Neurology 54 2000 1589 1595
68. P. Krack, A. Benazzouz, P. Pollak, P. Limousin, B. Piallat, D. Hoffmann, J. Xie, and A.L. Benabid Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation Mov. Disord. 13 1998 907 914
69. A.E. Lang Surgery for levodopa-induced dyskinesias Ann. Neurol. 47 2000 S193 S199 (discussion S199-S202)
70. A.E. Lang, A.M. Lozano, E. Montgomery, J. Duff, R. Tasker, and W. Hutchinson Posteroventral medial pallidotomy in advanced Parkinson's disease N. Engl. J. Med. 337 1997 1036 1042
71. J.W. Langston, M. Quik, G. Petzinger, M. Jakowec, and D.A. Di Monte Investigating levodopa-induced dyskinesias in the parkinsonian primate Ann. Neurol. 47 2000 S79 S89
72. T. Lee, P. Seeman, A. Rajput, I.J. Farley, and O. Hornykiewicz Receptor basis for dopaminergic supersensitivity in Parkinson's disease Nature 273 1978 59 61
73. P. LeWitt, D. Oakes, and L. Cui The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group Mov. Disord. 12 1997 183 189
74. A.M. Lozano, A.E. Lang, N. Galvez-Jimenez, J. Miyasaki, J. Duff, W.D. Hutchinson, and J.O. Dostrovsky Effect of GPi pallidotomy on motor function in Parkinson's disease Lancet 346 1995 1383 1387
75. A.M. Lozano, A.E. Lang, R. Levy, W. Hutchison, and J. Dostrovsky Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine Ann. Neurol. 47 2000 S141 S146
76. M. Lundblad, B. Picconi, H. Lindgren, and M.A. Cenci A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 16 2004 110 123
77. R. Marconi, D. Lefebvre-Caparros, A.M. Bonnet, M. Vidailhet, B. Dubois, and Y. Agid Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology Mov. Disord. 9 1994 2 12
78. E.R. Marcotte, R.M. Sullivan, and R.K. Mishra Striatal G-proteins: effects of unilateral 6-hydroxydopamine lesions Neurosci. Lett. 169 1994 195 198
79. C. Marin, A. Jimenez, E. Tolosa, M. Bonastre, and J. Bove Bilateral subthalamic nucleus lesion reverses l-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats Synapse 51 2004 140 150
80. C. Marras, M.P. McDermott, P.A. Rochon, C.M. Tanner, G. Naglie, A. Rudolph, and A.E. Lang Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort Neurology 64 2005 87 93
81. C.D.P. Marsden, J.D. Quinn, and N. Fluctuations of disability in Parkinson's disease: clinical aspects C.D. Marsden S. Fahn Movement Disorders 1981 Butterworth London 96 122
82. G. Meco, E. Fabrizio, A. Alessandri, N. Vanacore, and V. Bonifati Risperidone in levodopa induced dyskinesiae J. Neurol., Neurosurg. Psychiatry 64 1998 135
83. G. Meco, E. Fabrizio, S. Di Rezze, A. Alessandri, and L. Pratesi Mirtazapine in l-dopa-induced dyskinesias Clin. Neuropharmacol. 26 2003 179 181
84. I. Mendez, K.A. Baker, and M. Hong Simultaneous intrastriatal and intranigral grafting (double grafts) in the rat model of Parkinson's disease Brain Res. Brain Res. Rev. 32 2000 328 339
85. I. Mendez, A. Dagher, M. Hong, P. Gaudet, S. Weerasinghe, V. McAlister, D. King, J. Desrosiers, S. Darvesh, T. Acorn, and H. Robertson Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases J. Neurosurg. 96 2002 589 596
86. J.L. Molinuevo, F. Valldeoriola, E. Tolosa, J. Rumia, J. Valls-Sole, H. Roldan, and E. Ferrer Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease Arch. Neurol. 57 2000 983 988
87. J.L. Montastruc, O. Rascol, J.M. Senard, and A. Rascol A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up J. Neurol., Neurosurg. Psychiatry 57 1994 1034 1038
88. M. Morissette, M. Goulet, F. Calon, P. Falardeau, P.J. Blanchet, P.J. Bedard, and T. Di Paolo Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of l-3,4-dihydroxyphenylalanine Mol. Pharmacol. 50 1996 1073 1079
89. E. Moro, R.J. Esselink, A.L. Benabid, and P. Pollak Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation Brain 125 2002 2408 2417
90. M.M. Mouradian, J.L. Juncos, G. Fabbrini, and T.N. Chase Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies Ann. Neurol. 22 1987 475 479
91. M.M. Mouradian, I.J. Heuser, F. Baronti, and T.N. Chase Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease Ann. Neurol. 27 1990 18 23
92. H. Narabayashi, F. Yokochi, and Y. Nakajima Levodopa-induced dyskinesia and thalamotomy J. Neurol., Neurosurg. Psychiatry 47 1984 831 839
93. A. Nevet, G. Morris, G. Saban, N. Fainstein, and H. Bergman Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia J. Neurophysiol. 92 2004 1973 1981
94. J.G. Nutt Clinical pharmacology of levodopa-induced dyskinesia Ann. Neurol. 47 2000 S160 S164 (discussion S164-S166)
95. J.G. Nutt, and W.R. Woodward Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients Neurology 36 1986 739 744
96. J.G. Nutt, W.R. Woodward, J.H. Carter, and S.T. Gancher Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon Arch. Neurol. 49 1992 1123 1130
97. J.G. Nutt, J.H. Carter, E.S. Lea, and G.J. Sexton Evolution of the response to levodopa during the first 4 years of therapy Ann. Neurol. 51 2002 686 693
98. M.F. O'Neill, C. Heron-Maxwell, M.W. Conway, J.A. Monn, and P. Ornstein Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice Neuropharmacology 45 2003 565 574
99. J.A. Obeso, F. Grandas, M.T. Herrero, and R. Horowski The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease Eur. J. Neurosci. 6 1994 889 897
100. J.A. Obeso, C.W. Olanow, and J.G. Nutt Levodopa motor complications in Parkinson's disease Trends Neurosci. 23 2000 S2 S7
101. J.A. Obeso, M.C. Rodriguez-Oroz, M. Rodriguez, M.R. DeLong, and C.W. Olanow Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model Ann. Neurol. 47 2000 S22 S32 (discussion S32-S24)
102. J.A. Obeso, M.C. Rodriguez-Oroz, M. Rodriguez, J.L. Lanciego, J. Artieda, N. Gonzalo, and C.W. Olanow Pathophysiology of the basal ganglia in Parkinson's disease Trends Neurosci. 23 2000 S8 S19
103. C. Ohye Use of selective thalamotomy for various kinds of movement disorder, based on basic studies Stereotact. Funct. Neurosurg. 75 2000 54 65
104. C. Ohye, and T. Shibazaki Lesioning the thalamus for dyskinesia Stereotact. Funct. Neurosurg. 77 2001 33 39
105. Y. Oiwa, J.L. Eberling, D. Nagy, P. Pivirotto, M.E. Emborg, and K.S. Bankiewicz Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes Front. Biosci. 8 2003 a155 a166
106. C.W. Olanow, C. Mytilineou, and W. Tatton Current status of selegiline as a neuroprotective agent in Parkinson's disease Mov. Disord. 1 Suppl. 1 1998 55 58
107. C.W. Olanow, C.G. Goetz, J.H. Kordower, A.J. Stoessl, V. Sossi, M.F. Brin, K.M. Shannon, G.M. Nauert, D.P. Perl, J. Godbold, and T.B. Freeman A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease Ann. Neurol. 54 2003 403 414
108. E. Ongini Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction Neurology 61 2003 S72 S73
109. R.D. Page The use of thalamotomy in the treatment of levodopa-induced dyskinesia Acta Neurochir. (Wien) 114 1992 77 117
110. R.D. Page, M.A. Sambrook, and A.R. Crossman Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey Neuroscience 55 1993 147 165
111. S.M. Papa, and T.N. Chase Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys Ann. Neurol. 39 1996 574 578
112. S.M. Papa, and T.N. Chase Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys Ann. Neurol. 39 1996 574 578 (see comment)
113. S.M. Papa, R. Desimone, M. Fiorani, and E.H. Oldfield Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias Ann. Neurol. 46 1999 732 738
114. S.G. Parkin, R.P. Gregory, R. Scott, P. Bain, P. Silburn, B. Hall, R. Boyle, C. Joint, and T.Z. Aziz Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients Mov. Disord. 17 2002 682 692
115. Parkinson Study Group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa Ann. Neurol. 39 1996 37 45
116. Parkinson Study Group Mortality in DATATOP: a multicenter trial in early Parkinson's disease Ann. Neurol. 43 1998 318 325
117. Parkinson Study Group A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study Clin. Neuropharmacol. 23 2000 34 44
118. N.K. Patel, P. Heywood, K. O'Sullivan, R. McCarter, S. Love, and S.S. Gill Unilateral subthalamotomy in the treatment of Parkinson's disease Brain 126 2003 1136 1145
119. R.K. Pearce, M. Heikkila, I.B. Linden, and P. Jenner l-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations Psychopharmacology 156 2001 402 409
120. A. Peppe, J.M. Dambrosia, and T.N. Chase Risk factors for motor response complications in l-dopa-treated parkinsonian patients Adv. Neurol. 60 1993 698 702
121. P. Piccini Dyskinesias after transplantation in Parkinson's disease Lancet Neurol. 1 2002 472
122. A. Priori, G. Foffani, A. Pesenti, F. Tamma, A.M. Bianchi, M. Pellegrini, M. Locatelli, K.A. Moxon, and R.M. Villani Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease Exp. Neurol. 189 2004 369 379
123. M. Quik, S. Police, J.W. Langston, and D.A. Di Monte Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not l-DOPA-induced dyskinesias in the squirrel monkey Neuroscience 113 2002 213 220
124. A.H. Rajput, A. Rajput, A.E. Lang, R. Kumar, R.J. Uitti, and N. Galvez-Jimenez New use for an old drug: amantadine benefits levodopa-induced dyskinesia Mov. Disord. 13 1998 851
125. O. Rascol Medical treatment of levodopa-induced dyskinesias Ann. Neurol. 47 2000 S179 S188
126. O. Rascol The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease J. Neurol. 2 2000 II51 II57
127. A. Rascol, B. Guiraud, J.L. Montastruc, J. David, and M. Clanet Long-term treatment of Parkinson's disease with bromocriptine J. Neurol., Neurosurg. Psychiatry 42 1979 143 150
128. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. De Deyn, C.E. Clarke, and A.E. Lang A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N. Engl. J. Med. 342 2000 1484 1491
129. O. Rascol, I. Arnulf, H. Peyro-Saint Paul, C. Brefel-Courbon, M. Vidailhet, C. Thalamas, A.M. Bonnet, S. Descombes, B. Bejjani, N. Fabre, J.L. Montastruc, and Y. Agid Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease Mov. Disord. 16 2001 708 713
130. U.K. Rinne, F. Bracco, C. Chouza, E. Dupont, O. Gershanik, J.F. Marti Masso, J.L. Montastruc, and C.D. Marsden Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group Drugs 55 Suppl. 1 1998 23 30
131. J.F. Sassin Drug-induced dyskinesia in monkeys Adv. Neurol. 10 1975 47 54
132. I. Shoulson DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism Ann. Neurol. 44 1998 S160 S166
133. M.A. Silverdale, A.R. Crossman, and J.M. Brotchie Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia Exp. Neurol. 174 2002 21 28
134. K. Steece-Collier, T.J. Collier, P.D. Danielson, R. Kurlan, D.M. Yurek, and J.R. Sladek Jr. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats Mov. Disord. 18 2003 1442 1454
135. P.C. Su, H.M. Tseng, H.M. Liu, R.F. Yen, and H.H. Liou Treatment of advanced Parkinson's disease by subthalamotomy: one-year results Mov. Disord. 18 2003 531 538
136. T. Subramanian, and M. Deogaonkar Cell transplantation and gene therapy for the treatment of Parkinson's disease N. Galvez-Jimenez Scientific Basis for the Treatment of Parkinson's Disease 2005 Taylor and Francis London 233 250
137. M. Tomiyama, T. Kimura, T. Maeda, H. Tanaka, K. Kannari, and M. Baba Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine- lesioned rats intermittently treated with l-DOPA Synapse 52 2004 218 222
138. Tousi B., Subramanian, T., The effect of levetiracetam on levodopa induced dyskinesias in patients with Parkinson's disease, Parkinsonism Relat. Disord. (in press).
139. D. Vallone, M.T. Pellecchia, M. Morelli, P. Verde, G. DiChiara, and P. Barone Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins Brain Res. Mol. Brain Res. 52 1997 307 317
140. L. Verhagen Metman, P. Del Dotto, R. Natte, P. van den Munckhof, and T.N. Chase Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease Neurology 51 1998 203 206
141. M. Vidailhet, A.M. Bonnet, R. Marconi, F. Durif, and Y. Agid The phenomenology of l-dopa-induced dyskinesias in Parkinson's disease Mov. Disord. 1 1999 13 18
142. J.L. Vitek, R.A. Bakay, A. Freeman, M. Evatt, J. Green, W. McDonald, M. Haber, H. Barnhart, N. Wahlay, S. Triche, K. Mewes, V. Chockkan, J.Y. Zhang, and M.R. DeLong Randomized trial of pallidotomy versus medical therapy for Parkinson's disease Ann. Neurol. 53 2003 558 569
143. T. Wichmann, and M.R. DeLong Functional and pathophysiological models of the basal ganglia Curr. Opin. Neurobiol. 6 1996 751 758
144. T. Wichmann, and M.R. DeLong Functional neuroanatomy of the basal ganglia in Parkinson's disease Adv. Neurol. 91 2003 9 18
145. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186
146. M. Xu, R. Moratalla, L.H. Gold, N. Hiroi, G.F. Koob, A.M. Graybiel, and S. Tonegawa Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses Cell 79 1994 729 742
147. M.D. Yahr, R.C. Duvoisin, M.J. Schear, R.E. Barrett, and M.M. Hoehn Treatment of parkinsonism with levodopa Arch. Neurol. 21 1969 343 354
148. B.Y. Zeng, R.K. Pearce, G.M. MacKenzie, and P. Jenner Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l-DOPA Eur. J. Neurosci. 12 2000 1096 1104
149. B.Y. Zeng, L.A. Smith, R.K. Pearce, B. Tel, L. Chancharme, G. Moachon, and P. Jenner Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets Neurosci. Lett. 354 2004 6 9